Related Experiment Video
Updated: Aug 9, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Radiogenetic therapy: strategies to overcome tumor resistance
B Marples1, O Greco, M C Joiner
1Department of Radiation Oncology, Karmanos Cancer Institute and Wayne State University, Detroit, MI 48201-2013, USA. marplesb@kci.wayne.edu
Current Pharmaceutical Design
|October 8, 2003
Summary
Cancer gene therapy combines radiation-responsive or hypoxia-responsive promoters with suicide genes to target tumor cells. This approach enhances radiotherapy effectiveness, particularly for radioresistant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Cancer gene therapy aims to selectively eliminate malignant cells by exploiting tumor-specific traits.
- Strategies targeting common tumor features offer broad clinical applicability.
- Combining gene therapy with radiotherapy or exploiting tumor hypoxia are key research areas.
Purpose of the Study:
- To review two promising gene therapy methods for targeting tumor volume, suitable for combination with radiotherapy.
- To highlight methods exploiting radiation-responsive and hypoxia-responsive gene promoters.
Main Methods:
- Utilizing radiation-responsive gene promoters to control suicide gene expression in irradiated tissues.
- Employing oxygen-dependent promoters for therapeutic gene expression in hypoxic cells.
- Developing chimeric promoters combining radiation and hypoxia responsive elements for dual targeting.
Main Results:
- Radiation-responsive promoters enable targeted suicide gene expression and cell killing in conjunction with radiotherapy.
- Hypoxia-responsive promoters facilitate selective gene expression and prodrug activation in radioresistant hypoxic cells.
- Combined radiation and hypoxia responsive elements offer refined tumor targeting.
Conclusions:
- Gene therapy combined with radiotherapy shows significant potential for cancer treatment.
- This approach is particularly promising for cancers resistant to conventional radiotherapy due to inherent resistance or hypoxia.
- Further development of these targeted gene therapy strategies could improve patient outcomes.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...